Replies to post #589957 on NorthWest Biotherapeutics Inc (NWBO)

[CaptainObvious]

I'm liking that

[flipper44]

Good compromise

[dstock07734]

ATL,

Thanks for the post.

I am going to regurgitate something on the combination of dendritic cell with Poly-ICLC that the longs here already knew. My hope is that some newcomers might have a rough idea on how extraordinary are the results from DCVax-L combined with Poly-ICLC.

Several prominent scientists did the clinical trials using their own version of dendritic cells combined with poly-iclc for different indicators.

One of the them is Carolyn Britten, currently Vice President on Early Development Oncology at Amgen.

A Study of Vaccination With Poly-ICLC and Dendritic Cells in Patients With Pancreatic Adenocarcinoma
https://clinicaltrials.gov/ct2/show/NCT01677962?cond=dendritic+%2B+Hiltonol&draw=2&rank=2

A Feasibility and Safety Study of Vaccination With Poly-ICLC and Peptide-pulsed Dendritic Cells in Patients With Metastatic, Locally Advanced, Unresectable, or Recurrent Pancreatic Adenocarcinoma. This trial was in collaboration with Oncovir.
https://clinicaltrials.gov/ct2/show/NCT01410968?cond=dendritic+%2B+poly+iclc&draw=2&rank=3

Study of Vaccination With Poly-ICLC and Peptide-pulsed Dendritic Cells. This trial was terminated in the middle because of low enrollment.
https://clinicaltrials.gov/ct2/show/NCT01783431?cond=dendritic+%2B+poly+iclc&draw=2&rank=2

Nina Bhardwaj also did a clinical trial using the same combination with Oncovir as one of the collaborators.
A Comparison of Matured Dendritic Cells and Montanide® in Study Subjects With High Risk of Melanoma Recurrence
https://clinicaltrials.gov/ct2/show/NCT02334735?cond=dendritic+%2B+poly+iclc&draw=2&rank=5

Combined vaccination with NY-ESO-1 protein, poly-ICLC, and montanide improves humoral and cellular immune responses in high-risk melanoma patients
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6946846/

Here is the conclusion:
NY-ESO-1 protein in combination with poly-ICLC is safe, well-tolerated, and capable of inducing integrated antibody and CD4+ T-cell responses in most patients. Combination with montanide enhances antigen specific T-cell avidity and CD8+ T-cell cross-priming in a fraction of patients, indicating that montanide contributes to the induction of specific CD8+ T-cell responses to NY-ESO-1.

Ignacio Melero, who has been in close collaboration with BMY and his team did the following trial.
Phase II Study With Hiltonol and Dendritic Cells in Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT01734564?cond=dendritic+%2B+poly+iclc&draw=2&rank=4

Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients https://pubmed.ncbi.nlm.nih.gov/29554212/

Conclusions: This radio-immunotherapy combination strategy, aimed at resembling viral infection in tumor tissue in combination with a dendritic-cell vaccine and SABR, is safe and shows immune-associated activity and signs of preliminary clinical efficacy.